Phase 2 Schizophrenia Trial, Recruiting NCT06821945 Sponsor: Boryung Pharmaceutical Co., Ltd Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT06821945
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with schizophrenia (based on standard medical guidelines called DSM-5), and your doctor believes a lower-than-usual starting dose of the medication olanzapine is more appropriate for you based on your overall health
  • You have had schizophrenia for more than 1 year at the time of your first study visit

Who may not be able to join:

  • You have been diagnosed with a related but different mental health condition, such as schizoaffective disorder, bipolar disorder, or depressive disorder (based on DSM-5 guidelines), at the time of your first study visit
  • You have been admitted to a hospital due to worsening schizophrenia within the past 12 weeks before your first study visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82+2-708-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Boryung Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
30 May 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

The mean change of PANSS(Positive and Negative Syndrome Scale) total score; Incidence of treatment-emergent adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov